2 completed, 1 active not recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow ES102: new trials by email Literature Review of ES102 trials Research Report on ES102
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer ES102, Toripalimab - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Elpiscience (Suzhou) Biopharma, Ltd. | 30 | 2025-04-30 | 2026-10-20 |
| A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors ES102, JS001 - Solid Tumor, Neoplasms | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 30 | 2021-10-15 | 2025-06-23 |
| A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors ES102 - Solid Tumors, Neoplasms | Phase 1 | Completed | Elpiscience Biopharma, Ltd. | 18 | 2021-04-01 | 2025-06-23 |
Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1)
Elpiscience Biopharma, Ltd. (2) · Elpiscience (Suzhou) Biopharma, Ltd. (1)
China (3)